Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

FHS
June 12, 2024
10:52 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

Inhaled Glucocorticoid Flops for Speeding COVID Recovery in Outpatients

Inhaled fluticasone furoate failed to shorten recovery time for non-hospitalized adults with COVID-19, new data from the adaptive ACTIV-6 trial found. When used daily for

September 21, 2023

How Effective Are the Latest COVID Shots?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

February 4, 2024

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486 — a novel CD19xCD3 bispecific T-cell engager

January 3, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.